Humana (NYSE:HUM - Get Free Report) had its price objective cut by equities researchers at Jefferies Financial Group from $411.00 to $381.00 in a report released on Monday, Benzinga reports. The firm presently has a "buy" rating on the insurance provider's stock. Jefferies Financial Group's price objective suggests a potential upside of 17.12% from the company's previous close.
A number of other analysts also recently commented on the company. Argus downgraded Humana from a "buy" rating to a "hold" rating in a research report on Wednesday, March 13th. Truist Financial reissued a "hold" rating and issued a $550.00 price objective on shares of Humana in a report on Friday, January 19th. TheStreet lowered Humana from a "b" rating to a "c+" rating in a report on Monday, January 8th. Raymond James began coverage on Humana in a report on Friday, March 22nd. They issued a "market perform" rating on the stock. Finally, The Goldman Sachs Group dropped their price objective on Humana from $450.00 to $385.00 and set a "buy" rating on the stock in a report on Wednesday, April 3rd. Eleven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, Humana has a consensus rating of "Hold" and a consensus target price of $454.63.
Check Out Our Latest Stock Report on Humana
Humana Stock Performance
Shares of HUM traded down $3.03 during mid-day trading on Monday, reaching $325.30. The company had a trading volume of 1,562,992 shares, compared to its average volume of 1,992,417. Humana has a 52-week low of $299.23 and a 52-week high of $541.21. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $39.25 billion, a P/E ratio of 16.61, a PEG ratio of 1.92 and a beta of 0.45. The stock has a 50 day moving average of $330.40 and a two-hundred day moving average of $400.22.
Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of $0.76 by ($0.87). Humana had a return on equity of 19.44% and a net margin of 2.34%. The company had revenue of $26.46 billion during the quarter, compared to analysts' expectations of $25.47 billion. During the same quarter in the previous year, the company earned $1.62 EPS. The firm's quarterly revenue was up 17.9% compared to the same quarter last year. On average, analysts expect that Humana will post 16.06 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Jorge S. Mesquita acquired 545 shares of Humana stock in a transaction that occurred on Tuesday, February 20th. The shares were purchased at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the transaction, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.29% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Humana
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Altfest L J & Co. Inc. raised its position in Humana by 47.8% in the first quarter. Altfest L J & Co. Inc. now owns 1,036 shares of the insurance provider's stock valued at $359,000 after purchasing an additional 335 shares during the period. Leeward Investments LLC MA acquired a new stake in shares of Humana in the first quarter valued at $10,071,000. New Century Financial Group LLC acquired a new stake in shares of Humana in the first quarter valued at $1,183,000. Norden Group LLC grew its stake in shares of Humana by 3,471.6% in the first quarter. Norden Group LLC now owns 16,965 shares of the insurance provider's stock valued at $5,882,000 after buying an additional 16,490 shares in the last quarter. Finally, Plimoth Trust Co. LLC grew its stake in Humana by 39.5% during the 1st quarter. Plimoth Trust Co. LLC now owns 1,018 shares of the insurance provider's stock worth $353,000 after purchasing an additional 288 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.
Humana Company Profile
(
Get Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
